Trial Profile
An Open-label Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Booster Dose at 18-24 Months of Age in Healthy Toddlers in China.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Poliovirus vaccine inactivated (Primary)
- Indications Poliomyelitis
- Focus Adverse reactions
- Sponsors GSK
- 09 Dec 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 09 Dec 2009 Actual initiation date (Jun 2009) added as reported by ClinicalTrials.gov.
- 15 Aug 2009 Status changed from active, no longer recruiting to completed.